Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy

Genetics and Molecular Research

Volumn 13, Issue 4, 2014, Pages 9747-9755

  Zhang, L ^a   Hao, C Q ^b   Miao, L ^a   Dou, X G ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis C; Cytokine; Interferon; Pathogenesis; Serum; Th1 Th2 cell

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ALPHA2B INTERFERON PLUS RIBAVIRIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA; ALPHA INTERFERON; ANTIVIRUS AGENT; IL4 PROTEIN, HUMAN; IL5 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; MALE; NEUTROPHIL COUNT; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RNA SEQUENCE; TH1 CELL; TH2 CELL; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIRUS LOAD; BLOOD; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TH1 TH2 BALANCE; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; GENE EXPRESSION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TH1 CELLS; TH1-TH2 BALANCE; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84913573556     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.November.27.2     Document Type: Article

References (25)

1. Akira S (2000). The role of IL-18 in innate immunity. Curr. Opin. Immunol. 12: 59-63.
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, et al. (1992). The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N. Engl. J. Med. 327: 1899-1905.
3. Amoroso P, Rapicetta M, Tosti ME, Mele A, et al. (1998). Correlation between virus genotype and chronicity rate in acute hepatitis C. J. Hepatol. 28: 939-944.
4. Bozkaya H, Bozdayi AM, Aslan N, Turkay C, et al. (2000). Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment. Infection 28: 309-313.
5. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, et al. (1996). Immunoregulatory cytokines in chronic hepatitis C virus infection: pre-and posttreatment with interferon alfa. Hepatology 24: 6-9.
6. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, et al. (2006). Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 36: 144-150.
7. Falasca K, Mancino P, Ucciferri C, Dalessandro M, et al. (2007). Inflammatory cytokines and S-100b protein in patients with hepatitis C infection and cryoglobulinemias. Clin. Invest. Med. 30: E167-E176.
8. Gane EJ (2008). The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 14 (Suppl 2): S36-S44.
9. Inglot M, Gladysz A, Rymer W, Molin I, et al. (2008). Cytokine assessment in untreated hepatitis C virus infected patients and during interferon alpha+ribavirine therapy. Wiad. Lek. 61: 13-18.
10. Kogure T, Ueno Y, Fukushima K, Nagasaki F, et al. (2008). Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J. Gastroenterol. 14: 7225-4230.
11. Koziel MJ, Dudley D, Afdhal N, Grakoui A, et al. (1995). HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J. Clin. Invest. 96: 2311-2321.
12. Kwon JH and Bae SH (2008). Current status and clinical course of hepatitis C virus in Korea. Korean J. Gastroenterol. 51: 360-367.
13. Lapiński TW (2001). The levels of IL-1beta, IL-4 and IL-6 in the serum and the liver tissue of chronic HCV-infected patients. Arch. Immunol. Ther. Exp. 49: 311-316.
14. Lapiński TW and Dabrowska MM (2007). Activity of cytokines in chronic HCV-infected patients. Przegl. Epidemiol. 61: 747-754.
15. Majda-Stanisławska E, Pietrzak A and Brzezinska-Blaszczyk E (2008). Serum IL-18 concentration does not depend on the presence of HCV-RNA in serum or in PBMC. Hepatogastroenterology 55: 212-215.
16. Masuzaki R, Tateishi R, Yoshida H, Yoshida H, et al. (2008). Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J. Clin. Gastroenterol. 42: 839-843.
17. McGuinness PH, Painter D, Davies S and McCaughan GW (2000). Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 46: 260-269.
18. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, et al. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136: 2348-2357.
19. Napoli J, Bishop GA, McGuinness PH, Painter DM, et al. (1996). Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24: 759-765.
20. Priĭmiagi LS, Tefanova VT, Tallo TG, Shmidt EV, et al. (2003). Immune-regulating Th1-and Th2-cytokines in chronic infections caused by hepatitis B and C viruses. Vopr. Virusol. 48: 37-40.
21. Reiser M, Marousis CG, Nelson DR, Lauer G, et al. (1997). Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J. Hepatol. 26: 471-478.
22. Schvoerer E, Navas MC, Thumann C, Fuchs A, et al. (2003). Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. J. Med. Virol. 70: 588-593.
23. Seeff LB (1995). Natural history of viral hepatitis, type C. Semin. Gastrointest. Dis. 6: 20-27.
24. Trapero M, García-Buey L, Muñoz C, Vitón M, et al. (2005). Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C. Rev. Esp. Enferm. Dig. 97: 481-490.
25. Trepo C (2000). Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J. Viral Hepat. 7: 250-257.